Identifying NSCLC patients who will benefit from afatinib therapy using [18F]afatinib PET/CT

Eveline van de Stadt; Idris Bahce; Maqsood Yaqub; Alex Poot; E. Smit; Harry Hendrikse

Eveline van de Stadt
3Pulmonology VU University Medical Center Amsterdam Netherlands
Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
Idris Bahce
3Pulmonology VU University Medical Center Amsterdam Netherlands
Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
Maqsood Yaqub
1VU University Medical Center Amsterdam Netherlands
Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
Alex Poot
1VU University Medical Center Amsterdam Netherlands
Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
E. Smit
4Pulmonary Diseases VUMC Amsterdam Netherlands
Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
Harry Hendrikse
2Clinical Pharmacology and Pharmacy VU University Medical Center Amsterdam Netherlands
Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics

Article Figures & Data

Figures
Tables
Download figure
Open in new tab
Download powerpoint
Tables
Figures
Table 1. Post hoc univariate analysis of FC compared to EGFR mutational status (Tukey HSD test)
Significance
WT EGFR com+EGFR uncom+ 0.0030.000
EGFR com+ WTEGFR uncom+ 0.0030.941
EGFR uncom+ WT EGFR com+ 0.0000.941

Previous

Back to top

In this issue

Journal of Nuclear Medicine
Vol. 60, Issue supplement 1
May 1, 2019

Table of Contents
Index by author

Article Alerts

User Name *

Password *

Sign In to Email Alerts with your Email Address
Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.
NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Identifying NSCLC patients who will benefit from afatinib therapy using [18F]afatinib PET/CT

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Identifying NSCLC patients who will benefit from afatinib therapy using [¹⁸F]afatinib PET/CT

Eveline van de Stadt, Idris Bahce, Maqsood Yaqub, Alex Poot, E. Smit, Harry Hendrikse

Journal of Nuclear Medicine May 2019, 60 (supplement 1) 145;

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Share

Identifying NSCLC patients who will benefit from afatinib therapy using [¹⁸F]afatinib PET/CT

Eveline van de Stadt, Idris Bahce, Maqsood Yaqub, Alex Poot, E. Smit, Harry Hendrikse

Journal of Nuclear Medicine May 2019, 60 (supplement 1) 145;

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article
User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Info & Metrics

Related Articles
No related articles found.
Google Scholar
Cited By...
No citing articles found.
Google Scholar
More in this TOC Section
Oncology: Clinical Therapy and Diagnosis

Added value of single photon emission computed tomography (SPECT) / Computed Tomography (CT) with radioiodine whole body scan in follow up of patients with differentiated thyroid cancer

Assessment of incidental pituitary uptake on FDG PET/CT scan: Digital vs. conventional PET/CT

Thyroglobulin measurement in fine-needle aspiration optimize lateral neck dissection in patients with papillary thyroid cancer

Show more Oncology: Clinical Therapy and Diagnosis
Lung Cancer II: Targeted Therapies, Response to Treatment, and Prognosis

Combination of FDG and FMISO may predict accurate PFS in patients with early-stage NSCLC after stereotactic radiotherapy.

Early response and prognostic value of [¹⁸F]-FDG-PET/CT in 83 NSCLC patients treated with NIVOLUMAB

Metabolic Response Assessment Following Stereotactic Ablative Radiotherapy (SABR) in oligo lung metastases - How early we get to see!

Show more Lung Cancer II: Targeted Therapies, Response to Treatment, and Prognosis
Similar Articles

Main menu

User menu

Search

Identifying NSCLC patients who will benefit from afatinib therapy using [¹⁸F]afatinib PET/CT

Article Figures & Data

Figures

Tables

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Oncology: Clinical Therapy and Diagnosis

Lung Cancer II: Targeted Therapies, Response to Treatment, and Prognosis

Similar Articles